<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02495831</url>
  </required_header>
  <id_info>
    <org_study_id>Z7219J01</org_study_id>
    <nct_id>NCT02495831</nct_id>
  </id_info>
  <brief_title>Drug Interaction Study of Safinamide and a BCRP Substrate, Diclofenac, Concomitantly Administered to Healthy Volunteers</brief_title>
  <official_title>Drug Interaction Study of Safinamide and a BCRP Substrate, Diclofenac, Concomitantly Administered to Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zambon SpA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cross Research S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Zambon SpA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate if a single dose of safinamide 200 mg has an effect on the pharmacokinetics of
      diclofenamic acid, concomitantly administered as a single 50 mg diclofenac sodium dose, with
      respect to 50 mg diclofenac sodium administered alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to Xadago™ SmPC, safinamide may transiently inhibit BCRP, therefore a time interval
      of 5 h should be kept between dosing of safinamide and medicinal products that are BCRP
      substrates with a Tmax ≤2 h (e.g. diclofenac, pitavastatin, pravastatin, ciprofloxacin,
      methotrexate, topotecan or glyburide).

      Following a specific request of EMA CHMP, the present interaction study in healthy male and
      female volunteers was conducted to determine if co-administration of safinamide with a BCRP
      substrate alters plasma exposure of the BCRP substrate in vivo.

      Diclofenac was chosen among the other BCRP substrates considering its large use in the
      general population. Diclofenac in fact is an important analgesic and anti-inflammatory drug,
      widely used for the treatment of postoperative pain, rheumatoid arthritis, and chronic pain.
      Consequently, diclofenac is often used in combination regimens and undesirable drug-drug
      interactions may occur.

      Voltaren®, 50 mg soluble tablets, was selected among other possible diclofenac products
      because with this formulation peak concentration of diclofenamic acid is achieved at
      approximately 1 h, i.e. in less than 2 h.

      The present interaction study was designed in agreement with the FDA Guideline on Drug
      Interaction studies, taking also in consideration the EMA guideline on the Investigation of
      drug interactions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Evaluate Plasma Diclofenamic Acid Extent of Exposure Reported as Plasma AUC After Single Administration of 50 mg Diclofenac Sodium, With and Without Co-administration of a Single 200 mg Dose of Safinamide.</measure>
    <time_frame>24 hours</time_frame>
    <description>Plasma diclofenamic acid AUC0-t after T2 single dose, with and without T1 co-administration. To measure AUC plasma samples were taken by the participants at different time points, and the concentrations of diclofenac and safinamide were measured. AUC0-t is the area under the concentration-time curve from administration to the last observed concentration time t; PK parameters AUC0-t were analysed using analysis of variance (ANOVA). Before analysis, the data were transformed using a neperian logarithmic transformation. ANOVA was performed taking into account treatment, period, sequence and subject (sequence) as fixed effects with a variance components structure of the covariance matrix.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate Diclofenac Rate of Absorption Reported as Plasma Cmax After Single Administration of 50 mg Diclofenac With and Without 200 mg of Safinamide.</measure>
    <time_frame>24 hours</time_frame>
    <description>Cmax, of plasma diclofenamic acid after T2 single dose, with and without T1 co-administration. The parametric point estimators (PE) for the ratios of T2 treatment with T1 co-administration / T2 treatment without T1 co-administration for the PK parameters under consideration, and the two-sided 90% confidence interval (CI), were calculated using the adjusted least squares means (LSMEANS) from the ANOVA. LSmeans differences obtained in the log scale for Cmax were back-transformed to obtain the PE (i.e. geometric mean ratio) and the two-sided 90% CI as percentages.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax and T1/2</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lamda z</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Bioavailability (Frel)</measure>
    <time_frame>24 hours</time_frame>
    <description>calculated as ratio between AUC0-t (test) / AUC0-t (reference)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Diclofenac sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diclofenac sodium 50 mg oral tablets, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diclofenac sodium and safinamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diclofenac sodium 50 mg oral tablets, single dose, and safinamide 200 mg oral tablets, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac sodium</intervention_name>
    <description>Diclofenac sodium 50 mg single dose</description>
    <arm_group_label>Diclofenac sodium</arm_group_label>
    <other_name>Voltaren</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac sodium and safinamide</intervention_name>
    <description>Diclofenac 50 mg single dose and safinamide 200 mg single dose</description>
    <arm_group_label>Diclofenac sodium and safinamide</arm_group_label>
    <other_name>Voltaren and Xadago</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written informed consent before inclusion in the study

          2. Males and females, 25-55 years old

          3. Body Mass Index (BMI): 18.5-30 kg/m2

          4. Systolic blood pressure 100-139 mmHg, diastolic blood pressure 50-89 mmHg, heart rate
             50-90 bpm

          5. Ability to comprehend the full nature and purpose of the study

          6. Females of child-bearing potential must use at least one of the following :

        A non-hormonal intrauterine device or female condom with spermicide or contraceptive sponge
        with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2
        months before the screening visit A male sexual partner who agreed to use a male condom
        with spermicide A sterile sexual partner Female participants of non-child-bearing potential
        or in post-menopausal status for at least 1 year were admitted.

        Exclusion Criteria:

          1. Contraindications to MAO-B inhibitors, antiepileptic drugs, or to any NSAIDs

          2. Clinically significant abnormalities in ECG

          3. Clinically significant abnormal physical findings

          4. Clinically significant abnormal laboratory values

          5. Hypersensitivity or history of anaphylaxis to drugs or allergic reactions in general

          6. Significant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory,
             skin, haematological, endocrine or neurological diseases

          7. Medications, including over the counter medications and herbal remedies, NSAID or
             anticoagulant use for 2 weeks before and during the entire study; morphine or other
             similar opioids, SSRIs, SNRIs, tri- or tetracyclic antidepressant, tramadol,
             pethidine, dextromethorphan, MAO inhibitors, meperidine derivatives and antiepileptic
             drugs, medicinal products that are BCRP substrates, any known enzyme inhibiting or
             inducing agent within 4 weeks preceding the screening visit.

          8. Participation in the evaluation of any investigational product for 3 months before the
             study.

          9. Blood donations for 3 months before the study

         10. History of drug, alcohol, caffeine or tobacco abuse

         11. Positive drug test at screening or day -1

         12. Positive alcohol breath test at day -1

         13. Abnormal diets or substantial changes in eating habits in the 4 weeks before the
             study; vegetarians

         14. Positive or missing pregnancy test at screening or day -1, pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milko Radicioni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cross Research SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cross Research SA, Phase I Unit</name>
      <address>
        <city>Arzo</city>
        <state>Ticino</state>
        <zip>6864</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2015</study_first_submitted>
  <study_first_submitted_qc>July 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2015</study_first_posted>
  <results_first_submitted>January 22, 2016</results_first_submitted>
  <results_first_submitted_qc>April 14, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 15, 2016</results_first_posted>
  <last_update_submitted>April 14, 2016</last_update_submitted>
  <last_update_submitted_qc>April 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PK study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Bioequivalence data are to be considered as a whole in all subjects (90%CI).</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment started and finished on May 2015 and the study was performed in Switzerland at CROSS Research S.A., Phase I Unit, Via F.A. Giorgioli 14 CH-6864 Arzo, Switzerland</recruitment_details>
      <pre_assignment_details>Twenty-four (24) subjects were randomised in the study. One of the 24 subjects discontinued the study before study treatment. Twenty-two (22) subjects completed the study per protocol.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Diclofenac Sodium First, Safinamide + Diclofenac Sodium Second</title>
          <description>Diclofenac sodium 50 mg oral tablets, single dose, and safinamide 200 mg oral tablets, single dose</description>
        </group>
        <group group_id="P2">
          <title>Safinamide + Diclofenac Sodium First, Diclofenac Sodium Second</title>
          <description>Diclofenac sodium 50 mg oral tablets, single dose Safinamide 200 mg oral tablets, single dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12">One participant withdrew at the end of period 1</participants>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>males and females healthy volunteers, age 22-55 inclusive. This is a cross-over study, so 23 subjects were enrolled in total and participated in both groups</population>
      <group_list>
        <group group_id="B1">
          <title>Intervention</title>
          <description>Diclofenac sodium 50 mg oral tablets, single dose
Diclofenac sodium 50 mg oral tablets, single dose and safinamide 200 mg oral tablets, single dose</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>healthy volunteers, both sexes, 22-55 years old inclusive</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.6" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Evaluate Plasma Diclofenamic Acid Extent of Exposure Reported as Plasma AUC After Single Administration of 50 mg Diclofenac Sodium, With and Without Co-administration of a Single 200 mg Dose of Safinamide.</title>
        <description>Plasma diclofenamic acid AUC0-t after T2 single dose, with and without T1 co-administration. To measure AUC plasma samples were taken by the participants at different time points, and the concentrations of diclofenac and safinamide were measured. AUC0-t is the area under the concentration-time curve from administration to the last observed concentration time t; PK parameters AUC0-t were analysed using analysis of variance (ANOVA). Before analysis, the data were transformed using a neperian logarithmic transformation. ANOVA was performed taking into account treatment, period, sequence and subject (sequence) as fixed effects with a variance components structure of the covariance matrix.</description>
        <time_frame>24 hours</time_frame>
        <population>healthy volunteers</population>
        <group_list>
          <group group_id="O1">
            <title>Diclofenac Sodium</title>
            <description>Diclofenac sodium 50 mg oral tablets, single dose
Diclofenac sodium: Diclofenac sodium 50 mg single dose</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac Sodium and Safinamide</title>
            <description>Diclofenac sodium 50 mg oral tablets, single dose, and safinamide 200 mg oral tablets, single dose
Diclofenac sodium and safinamide: Diclofenac 50 mg single dose and safinamide 200 mg single dose</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate Plasma Diclofenamic Acid Extent of Exposure Reported as Plasma AUC After Single Administration of 50 mg Diclofenac Sodium, With and Without Co-administration of a Single 200 mg Dose of Safinamide.</title>
          <description>Plasma diclofenamic acid AUC0-t after T2 single dose, with and without T1 co-administration. To measure AUC plasma samples were taken by the participants at different time points, and the concentrations of diclofenac and safinamide were measured. AUC0-t is the area under the concentration-time curve from administration to the last observed concentration time t; PK parameters AUC0-t were analysed using analysis of variance (ANOVA). Before analysis, the data were transformed using a neperian logarithmic transformation. ANOVA was performed taking into account treatment, period, sequence and subject (sequence) as fixed effects with a variance components structure of the covariance matrix.</description>
          <population>healthy volunteers</population>
          <units>h X ng per mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1323.28" spread="390.53"/>
                    <measurement group_id="O2" value="1381.32" spread="393.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The PK parameters AUC0-t and Cmax were analysed using analysis of variance (ANOVA). Before analysis, the data were transformed using a neperian logarithmic transformation. ANOVA was performed taking into account treatment, period, sequence and subject (sequence) as fixed effects with a variance components structure of the covariance matrix.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1</p_value>
            <p_value_desc>If the upper limit of the 90% confidence interval is &lt; 125.00%, no effect of safinamide on diclofenamic acid bioavailability is present (no interaction present).</p_value_desc>
            <method>ANOVA</method>
            <param_type>point estimate (ratio of geometric means</param_type>
            <param_value>90</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>80</ci_lower_limit>
            <ci_upper_limit>125</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate Diclofenac Rate of Absorption Reported as Plasma Cmax After Single Administration of 50 mg Diclofenac With and Without 200 mg of Safinamide.</title>
        <description>Cmax, of plasma diclofenamic acid after T2 single dose, with and without T1 co-administration. The parametric point estimators (PE) for the ratios of T2 treatment with T1 co-administration / T2 treatment without T1 co-administration for the PK parameters under consideration, and the two-sided 90% confidence interval (CI), were calculated using the adjusted least squares means (LSMEANS) from the ANOVA. LSmeans differences obtained in the log scale for Cmax were back-transformed to obtain the PE (i.e. geometric mean ratio) and the two-sided 90% CI as percentages.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diclofenac Sodium</title>
            <description>Diclofenac sodium 50 mg oral tablets, single dose
Diclofenac sodium: Diclofenac sodium 50 mg single dose</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac Sodium and Safinamide</title>
            <description>Diclofenac sodium 50 mg oral tablets, single dose, and safinamide 200 mg oral tablets, single dose
Diclofenac sodium and safinamide: Diclofenac 50 mg single dose and safinamide 200 mg single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate Diclofenac Rate of Absorption Reported as Plasma Cmax After Single Administration of 50 mg Diclofenac With and Without 200 mg of Safinamide.</title>
          <description>Cmax, of plasma diclofenamic acid after T2 single dose, with and without T1 co-administration. The parametric point estimators (PE) for the ratios of T2 treatment with T1 co-administration / T2 treatment without T1 co-administration for the PK parameters under consideration, and the two-sided 90% confidence interval (CI), were calculated using the adjusted least squares means (LSMEANS) from the ANOVA. LSmeans differences obtained in the log scale for Cmax were back-transformed to obtain the PE (i.e. geometric mean ratio) and the two-sided 90% CI as percentages.</description>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="766.59" spread="390.01"/>
                    <measurement group_id="O2" value="833.50" spread="443.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>geometric mean ratio</param_type>
            <param_value>104.84</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.40</ci_lower_limit>
            <ci_upper_limit>114.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax and T1/2</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diclofenac Sodium</title>
            <description>Diclofenac sodium 50 mg oral tablets, single dose
Diclofenac sodium: Diclofenac sodium 50 mg single dose</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac Sodium and Safinamide</title>
            <description>Diclofenac sodium 50 mg oral tablets, single dose, and safinamide 200 mg oral tablets, single dose
Diclofenac sodium and safinamide: Diclofenac 50 mg single dose and safinamide 200 mg single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax and T1/2</title>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="0.41"/>
                    <measurement group_id="O2" value="1.0" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T1/2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" spread="0.43"/>
                    <measurement group_id="O2" value="1.19" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lamda z</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diclofenac Sodium</title>
            <description>Diclofenac sodium 50 mg oral tablets, single dose
Diclofenac sodium: Diclofenac sodium 50 mg single dose</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac Sodium and Safinamide</title>
            <description>Diclofenac sodium 50 mg oral tablets, single dose, and safinamide 200 mg oral tablets, single dose
Diclofenac sodium and safinamide: Diclofenac 50 mg single dose and safinamide 200 mg single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Lamda z</title>
          <units>1/hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="0.22"/>
                    <measurement group_id="O2" value="0.63" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Bioavailability (Frel)</title>
        <description>calculated as ratio between AUC0-t (test) / AUC0-t (reference)</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diclofenac Sodium</title>
            <description>Diclofenac sodium 50 mg oral tablets, single dose
Diclofenac sodium: Diclofenac sodium 50 mg single dose</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac Sodium and Safinamide</title>
            <description>Diclofenac sodium 50 mg oral tablets, single dose, and safinamide 200 mg oral tablets, single dose
Diclofenac sodium and safinamide: Diclofenac 50 mg single dose and safinamide 200 mg single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Bioavailability (Frel)</title>
          <description>calculated as ratio between AUC0-t (test) / AUC0-t (reference)</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.67" spread="28.84"/>
                    <measurement group_id="O2" value="109.61" spread="32.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Diclofenac Sodium</title>
          <description>Diclofenac sodium 50 mg oral tablets, single dose</description>
        </group>
        <group group_id="E2">
          <title>Diclofenac Sodium and Safinamide</title>
          <description>Diclofenac sodium 50 mg oral tablets, single dose, and safinamide 200 mg oral tablets, single dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>no limitations</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Milko Radicioni</name_or_title>
      <organization>CROSS REsearch SA</organization>
      <phone>+41.91.63.00 ext 510</phone>
      <email>clinic@croalliance.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

